Atrial Fibrillation (AFib) Support Group
Atrial fibrillation (AF or afib) is an abnormal heart rhythm (cardiac arrhythmia) which involves the two small, upper heart chambers (the atria). Heart beats in a normal heart begin after electricity generated in the atria by the sinoatrial node spread through the heart and cause contraction of the heart muscle and pumping of blood.

As a trail runner, falling is inevitable. Every once in a while, a rock or root gets bored and reaches up, grabs my toe and throws me down. About 10 years ago I slipped on a rock and crushed my nose while running across a stream. I had quite a nose bleed for a couple of hours. I know the hazard.
And since I've noticed more problems with balance, I've been working with a trainer to try to reduce the risk of losing my balance.
So not having an antidote was one reason I didn't consider the NOACs. Plus the cardiologist steered me away from them for the same reason.
I've contacted my cardiologist and asked to be put on one of the NOACs, preferably Eliquis. It sounds like a better choice for me.
Todd
http://healthcare.globaldata.com/resources/expert-insights/pharmaceuticals/portolas-noac-antidote-benefits-from-big-pharma-collaborations-and-phase-iii-study-initiation
The reversal agent is for factor XA drugs (Xarelto and Eliquis) being developed by Portola Pharmaceuticals. The drug is called andexanet alfa. Sounds like they are in phase 2 trials.
From the company web site:
http://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/
November 18, 2013
Data from First Phase I Study of Antidote for Pradaxa (dabigatran etexilate mesylate) Presented at American Heart Association Scientific Sessions
Data indicate the antidote may be able to achieve immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy humans
Ridgefield, CT, November 18, 2013 Boehringer Ingelheim Pharmaceuticals, Inc. today announced results showing that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers. These results, presented today during the American Heart Associations Scientific Sessions 2013, represent the first clinical data involving the compound, which was discovered and developed by the company.
Testing is going on now.
petey
http://blogs.nature.com/spoonful/2013/03/antidotes-edge-closer-to-reversing-effects-of-new-blood-thinners.html